Benitec Biopharma Inc.
BNTC
$12.78
-$1.01-7.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 18.94% | 60.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.33% | 48.68% | |||
| Operating Income | -18.33% | -48.68% | |||
| Income Before Tax | -27.14% | -45.42% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -27.14% | -45.42% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -27.14% | -45.42% | |||
| EBIT | -18.33% | -48.68% | |||
| EBITDA | -18.37% | -49.08% | |||
| EPS Basic | 27.30% | 29.88% | |||
| Normalized Basic EPS | 27.27% | 29.87% | |||
| EPS Diluted | 27.30% | 29.88% | |||
| Normalized Diluted EPS | 27.27% | 29.87% | |||
| Average Basic Shares Outstanding | 74.85% | 107.39% | |||
| Average Diluted Shares Outstanding | 74.85% | 107.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||